Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1274.668
- +6.574+0.52%
Vertex Announces U.S. FDA Approval For TRIKAFTA To Include Additional Non-F508del TRIKAFTA-Responsive Variants
UBS Says 'Underweight the Names With High China Exposure'
J.P. Morgan's Top Healthcare Stocks for 2025
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
CRISPR Therapeutics Analyst Ratings
Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold
The Dow barely ended its longest continuous decline in 50 years, Micron fell by 16%, the US dollar reached a two-year high again, and US bonds, oil, and Bitcoin all dropped.
U.S. stock market's other Indexes turned down towards the end, Tesla rose by nearly 4% before closing down, NVIDIA reached a high of 4%, and Micron Technology had its steepest decline in five years. The yield on the 10-year U.S. Treasury bonds briefly increased by nearly 10 basis points approaching 4.60%, close to a seven-month high, while short-term bond yields fell, with the 2/10-year yield spread at its widest in two and a half years. The Bank of England held rates steady, but more officials supported a rate cut, leading to a decline in the British Pound. The Governor of the Bank of Japan suppressed interest rate hike expectations, causing the yen to fall towards 158, and the offshore renminbi briefly dropped below 7.32 yuan to its lowest in 15 months. Bitcoin fell by 5%, approaching $0.096 million. Spot Gold rose by 1.6% before narrowing back below $2,600, while the futures silver fell by 5%, and U.S. crude oil fell below $70.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Vertex Downgraded to Perform by Oppenheimer
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Vertex's Non-opioid Drug Succeeds in Back Pain Trial
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Vertex Pharmaceuticals Announced Results From Its Phase 2 Study Of Suzetrigine For Painful Lumbosacral Radiculopathy, The Study Met Its Primary Endpoint With Statistically Significant And Clinically Meaningful Reduction In Pain On The Numeric Pain...
Biggest Stock Movers Thursday: MU, MESO, and More
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year